Company / Cost of Revenue
BioMarin Pharmaceutical Cost of Revenue History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
$717.4M
FY2025
5-year range
$470.5M / $717.4M
FY2021-FY2025
Trend
+23.6%
vs FY2024
Sector context
#20 of 85
Health Care
What the data says
BioMarin Pharmaceutical's cost of revenue of $717M is higher than 76% of companies in the Health Care sector (FY2025). Cost of Revenue has increased for 4 consecutive years, from $471M in FY2021 to $717M in FY2025.
Based on SEC 10-K filings.
$717M in FY2025 with a 5-year CAGR of +6.5%. Top quartile in the Health Care sector.
Increased from $532M to $717M over the past 2 years.
Health Care sector context is included.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- +12.6%
- 5-Year CAGR
- +6.5%
- 10-Year CAGR
- -
Sector benchmark
-63.8% below sector average
Key checks
Key Insights
- BioMarin Pharmaceutical's cost of revenue has grown for 4 consecutive years.
- 5-year CAGR of +6.5%, indicating consistent growth.
- In FY2025, cost of revenue increased 23.6% year-over-year.
- Ranks #20 out of 85 companies in the Health Care sector.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $717.4M | +23.6% |
| FY2024 | $580.2M | +9.1% |
| FY2023 | $532.1M | +5.8% |
| FY2022 | $503.0M | +6.9% |
| FY2021 | $470.5M | -10.3% |
| FY2020 | $524.3M | +45.8% |
| FY2019 | $359.5M | +14.0% |
| FY2018 | $315.3M | +30.4% |
| FY2017 | $241.8M | +15.3% |
| FY2016 | $209.6M | +37.9% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026